<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208701</url>
  </required_header>
  <id_info>
    <org_study_id>EBP-FHC-2010-3</org_study_id>
    <nct_id>NCT01208701</nct_id>
  </id_info>
  <brief_title>The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy</brief_title>
  <acronym>STAD</acronym>
  <official_title>The Effect of Atorvastatin on the NO-system in Patients With Type 2 Diabetes and Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erling Bjerregaard Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been documented that statin reduce mortality and morbidity in patients with
      cardiovascular disease. This effect can partly be related to a reduction in cholesterol
      levels in blood. Nitric oxide (NO) production is reduced in several chronic diseases such as
      nephropathy, diabetes and hypertension. The purpose of this study is to investigate the
      effect of Atorvastatin treatment on the NO-system measuring renal and cardiovascular
      variables in patients with type 2 diabetes with nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be examined on two examination days. 4 days prior to each examination day
      subjects are treated with either atorvastatin or placebo. During treatment periods subject
      are given a standardized diet.

      On the examination days subject are given L-NMMA(L-NG-monomethyl Arginine citrate), a NO
      inhibitor, 6 mg bolus infusion followed by continuous 4 mg/kg/hr infusion for 1 hour. Renal
      function, central hemodynamic and vasoactive hormones are evaluated prior, during and after
      L-NMMA infusion.

      Renal function is measured by renal clearance of 51Cr-EDTA and urinary sodium, potassium and
      albumin concentration. Urinary excretion of protein from sodium channels such as the NaCl
      cotransporter (NCC), the Na-K-Cl cotransporter (NKCC) and the epithelial sodium channel
      (ENaC) will be measured to evaluate channel activity in the nephron.

      Central blood pressure, pulse wave analysis, and augmentation index are measured using
      SphygmoCorÂ® from Atcor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional excretion of sodium</measure>
    <time_frame>5 days treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma angiotensin II concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of protein from sodium channels such as the NaCl cotransporter (NCC), the Na-K-Cl cotransporter (NKCC) and the epithelial sodium channel (ENaC)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentations index</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Nephropathy</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Zarator, 80 mg pr day for 5 days</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Zarator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unikalk</intervention_name>
    <description>1 tablet Unikalk pr day for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  minimum 40 years

          -  Chronic Kidney disease

          -  Estimated GFR (eGFR) between 30 and 90 ml/min

          -  Diabetes Mellitus type II

        Exclusion Criteria:

          -  Nephrotic Syndrome

          -  Anamnestic or clinical signs of significant heart, lung, lever, kidney and brain
             disease

          -  Neoplastic disease

          -  Alcohol abuse,

          -  Drug abuse

          -  Pregnancy or nursing

          -  Blood donation within a month before examination

          -  Hgb &lt; 6,0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank H Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicinsk Forskning, Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>professor chief physician</investigator_title>
  </responsible_party>
  <keyword>Atorvastatin</keyword>
  <keyword>L-NMMA</keyword>
  <keyword>NO</keyword>
  <keyword>Nephrology</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

